Good MorningEquity markets extended their gains on Wednesday following a better-than-expected Retail Sales figure and healthy reports from retailers Target and The TJX Companies. Both produced substantial bottom-line strength, although the causes were different. In the case of TJX Companies, sales traffic led to revenue growth and margin leverage, while Target leaned into discounts to reduce inventory. The takeaway is that consumers remain resilient if price-conscious and in search of bargains.
The S&P 500 advanced about 0.5% at the session high, but weakness started to show; by the end of the session, the market was trading near break-even. The day's candle stick formation is a small spinning top with a visible upper shadow that reveals resistance below critical levels. Because the market is overbought at current levels and trading within an established range, it will likely sell off soon without another catalyst to drive it higher. The earnings season is all but over, and there are no major economic reports due until after the Thanksgiving Holiday so another catalyst may be hard to come by. Featured: How A.I. Could Make Most 21st Century Diseases EXTINCT (Behind the Markets) 
|
Stocks | | |
Warren Buffett is widely regarded as the most well-known, famous, and successful investor of all time. As such, his investment decisions and changes to his holdings are closely monitored and highly anticipated by the investing community.
His company, financial heavyweight Berkshire Hathaway... Read the Full Story >> |
|
From Our Partners50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. | | | | Learn more here. |
|
Markets | | |
The world of financial markets can be a brutal jungle, filled with dangers at every turn and businesses going bankrupt or turning billionaires almost overnight. Today, some of these risks and uncertain turning points have been assessed to bring you a sensible list of companies that can be termed a... Read the Full Story >> |
|
Markets | | | President Joe Biden has made America's case to CEOs attending the Asia-Pacific summit in San Francisco that the United States is committed to high standards in trade that will benefit economies across the Pacific Read the Full Story >> |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | Go HERE to Reveal Which Stock These Are |
|
Stocks | | |
The big retailers have begun to report, and news from Target (NYSE: TGT) and TJX Companies (NYSE: TJX) has their shares moving in opposite directions. Target is up nearly 15%, and The TJX Companies is down about 3% following their Q3 releases. Nevertheless, Target shares will likely hit a new low ... Read the Full Story >> |
|
Markets | | |
Ambarella (NASDAQ: AMBA) reported some game-changing news for investors. The company was chosen to provide microchips for an automotive industry first. A start-up and joint venture between Ford Motor (NYSE: F) and ADT (NYSE: ADT) called Canopy uses the CVFlow SoC to power its aftermarket truck-bed... Read the Full Story >> |
|
From Our PartnersFor investors, this may be the biggest tech opportunity you'll see in your lifetime. (HINT: It's not who you think.) | | Go HERE for details |
|
Stocks | | |
In what’s shaping up to be another strong week for U.S. equities, traders have much to be thankful for heading into Thanksgiving week.
November 14th’s headline Consumer Price Index (CPI) reading for October came in at a cooler-than-expected 3.2%. The market cheered the result because ... Read the Full Story >> |
|
Markets | | | When you don’t have any money, it can be stressful. Don’t let that stop you from being productive. Even if you’re on a tight budget, you can still improve your life and reach your goals. When you don’t have any money, here are 20 productive things you can do. 1. Hold a bill-lowering session. Are […]
The post 20 Productive Things to Do When You Have No Money appeared first on Due.
Read the Full Story >> |
|
Markets | | | If your young one loves applesauce, they might be a risk for a potentially life-threatening level of lead poisoning, according to a new report from the Center for Disease Control.On Monday, the CDC issued a warning telling doctors to be on alert for lead poisoning after 22 toddlers in 14 states were... Read the Full Story >> |
|
Markets | | | Russia's State Duma took a step forward Wednesday towards approving its biggest-ever federal budget which will increase spending by around 25% in 2024, with record amounts going on defense.Defense spending is expected to overtake social spending next year for the first time in modern Russian history... Read the Full Story >> |
|
Markets | | | Sephora is removing all perfumes from the sales floor to stop in-store theft.The multinational makeup retailer is known for its try-before-you-buy strategy, but the company says it was forced to put fragrances behind lock and key to stop customers from stealing, per CNN.Previously, customers were ab... Read the Full Story >> |
|
The Early Bird Stock Of The DayThursday: Stock With Recent Earnings Beat Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. | | View Today's Stock Pick |
|
